Identification of major factors associated with failed clinical molecular oncology testing performed by next generation sequencing (NGS)

Molecular Oncology

Volumn 9, Issue 9, 2015, Pages 1737-1743

  Al Kateb, Hussam ^a   Nguyen, TuDung T ^a   Steger May, Karen ^a   Pfeifer, John D ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Diagnostic biopsy; DNA degradation and purity; Failed analysis; Molecular oncology testing by NGS; Number of cores; Site and type of biopsy

Indexed keywords

DNA;

AGE; ANALYTICAL ERROR; ARTICLE; BIOPSY; CELL VIABILITY; DNA DEGRADATION; DNA PURITY; DNA SEQUENCE; GENE AND NUCLEIC ACID PARAMETERS; HUMAN; HUMAN TISSUE; NEXT GENERATION SEQUENCING; PRIORITY JOURNAL; COHORT ANALYSIS; GENETICS; HIGH THROUGHPUT SEQUENCING; NEOPLASMS; PROCEDURES; SENSITIVITY AND SPECIFICITY;

COHORT STUDIES; DNA; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; NEOPLASMS; SENSITIVITY AND SPECIFICITY; SEQUENCE ANALYSIS, DNA;

EID: 84945466512     PISSN: 15747891     EISSN: 18780261     Source Type: Journal    
DOI: 10.1016/j.molonc.2015.05.004     Document Type: Article

References (29)

1. Benavides J., García-Pariente C., Gelmetti D., Fuertes M., Ferreras M.C., García-Marín J.F., Pérez V. Effects of fixative type and fixation time on the detection of Maedi Visna virus by PCR and immunohistochemistry in paraffin-embedded ovine lung samples. J. Virol. Methods 2006, 137(2):317-324.
2. Cottrell C.E., Al-Kateb H., Bredemeyer A.J., Duncavage E.J., Spencer D.H., Abel H.J., Lockwood C.M., Hagemann I.S., O'Guin S.M., Burcea L.C., et al. Validation of a next-generation sequencing assay for clinical molecular oncology. J. Mol. Diagn.: JMD 2014, 16:89-105.
3. Doyle L.A., Wong K.K., Bueno R., Dal Cin P., Fletcher J.A., Sholl L.M., Kuo F. Ewing sarcoma mimicking atypical carcinoid tumor: detection of unexpected genomic alterations demonstrates the use of next generation sequencing as a diagnostic tool. Cancer Genet. 2014, 207:335-339.
4. Dudley J., Tseng L.H., Rooper L., Harris M., Haley L., Chen G., Gocke C.D., Eshleman J.R., Lin M.T. Challenges posed to pathologists in the detection of KRAS mutations in colorectal cancers. Arch. Pathol. Lab. Med. 2015, 139:211-218.
5. Frampton G.M., Fichtenholtz A., Otto G.A., Wang K., Downing S.R., He J., Schnall-Levin M., White J., Sanford E.M., An P., et al. Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing. Nat. Biotechnol. 2013, 31:1023-1031.
6. Frederick L., Beardell F., Viswanatha D.S. Novel BCR-ABL1 fusion identified by targeted next-generation sequencing in a patient with an atypical myeloproliferative neoplasm. Hum. Pathol. 2014, 45:1784-1789.
7. Gerlinger M., Rowan A.J., Horswell S., Larkin J., Endesfelder D., Gronroos E., Martinez P., Matthews N., Stewart A., Tarpey P., et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. New Engl. J. Med. 2012, 366:883-892.
8. Greer C.E., Peterson S.L., Kiviat N.B., Manos M.M. PCR amplification from paraffin-embedded tissues. Effects of fixative and fixation time. Am. J. Clin. Pathol. 1991, 95(2):117-124.
9. Hagemann I.S., Devarakonda S., Lockwood C.M., Spencer D.H., Guebert K., Bredemeyer A.J., Al-Kateb H., Nguyen T.T., Duncavage E.J., Cottrell C.E., et al. Clinical next-generation sequencing in patients with non-small cell lung cancer. Cancer 2015, 121:631-639.
10. Heitzer E., Auer M., Gasch C., Pichler M., Ulz P., Hoffmann E.M., Lax S., Waldispuehl-Geigl J., Mauermann O., Lackner C., et al. Complex tumor genomes inferred from single circulating tumor cells by array-CGH and next-generation sequencing. Cancer Res. 2013, 73:2965-2975.
11. Jackson V. Studies on histone organization in the nucleosome using formaldehyde as a reversible cross-linking agent. Cell 1978, 15(3):945-954.
12. Kanagal-Shamanna R., Portier B.P., Singh R.R., Routbort M.J., Aldape K.D., Handal B.A., Rahimi H., Reddy N.G., Barkoh B.A., Mishra B.M., et al. Next-generation sequencing-based multi-gene mutation profiling of solid tumors using fine needle aspiration samples: promises and challenges for routine clinical diagnostics. Modern Patholo.: Official J. United States Can. Acad. Pathol. Inc. 2014, 27:314-327.
13. Karnes H.E., Duncavage E.J., Bernadt C.T. Targeted next-generation sequencing using fine-needle aspirates from adenocarcinomas of the lung. Cancer Cytopathol. 2014, 122:104-113.
14. Kris M.G., Johnson B.E., Berry L.D., Kwiatkowski D.J., Iafrate A.J., Wistuba I.I., Varella-Garcia M., Franklin W.A., Aronson S.L., Su P.F., et al. Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs. JAMA 2014, 311:1998-2006.
15. Lin M.T., Mosier S.L., Thiess M., Beierl K.F., Debeljak M., Tseng L.H., Chen G., Yegnasubramanian S., Ho H., Cope L., et al. Clinical validation of KRAS, BRAF, and EGFR mutation detection using next-generation sequencing. Am. J. Clin. Pathol. 2014, 141:856-866.
16. Macaulay I.C., Voet T. Single cell genomics: advances and future perspectives. PLoS Genet. 2014, 10:e1004126.
17. Marcucci G., Yan P., Maharry K., Frankhouser D., Nicolet D., Metzeler K.H., Kohlschmidt J., Mrozek K., Wu Y.Z., Bucci D., et al. Epigenetics meets genetics in acute myeloid leukemia: clinical impact of a novel seven-gene score. J. Clin. Oncol. Official J. Am. Soc. Clin. Oncol. 2014, 32:548-556.
18. Martinez-Lopez J., Lahuerta J.J., Pepin F., Gonzalez M., Barrio S., Ayala R., Puig N., Montalban M.A., Paiva B., Weng L., et al. Prognostic value of deep sequencing method for minimal residual disease detection in multiple myeloma. Blood 2014, 123:3073-3079.
19. Nawy T. Single-cell sequencing. Nat. Methods 2014, 11:18.
20. Pritchard C.C., Salipante S.J., Koehler K., Smith C., Scroggins S., Wood B., Wu D., Lee M.K., Dintzis S., Adey A., et al. Validation and implementation of targeted capture and sequencing for the detection of actionable mutation, copy number variation, and gene rearrangement in clinical cancer specimens. J. Mol. Diagn.: JMD 2014, 16:56-67.
21. Renovanz M., Kim E.L. Intratumoral heterogeneity, its contribution to therapy resistance and methodological caveats to assessment. Front. Oncol. 2014, 4:142.
22. Sehn J.K., Hagemann I.S., Pfeifer J.D., Cottrell C.E., Lockwood C.M. Diagnostic utility of targeted next-generation sequencing in Problematic cases. Am. J. Surg. Pathol. 2014, 38:534-541.
23. Sehn J.K., Spencer D.H., Pfeifer J.D., Bredemeyer A.J., Cottrell C.E., Abel H.J., Duncavage E.J. Occult specimen contamination in routine clinical NGS testing. Am. J. Clin. Pathol. 2015, (in press).
24. Simen B.B., Yin L., Goswami C.P., Davis K.O., Bajaj R., Gong J.Z., Peiper S.C., Johnson E.S., Wang Z.X. Validation of a next-generation-sequencing cancer panel for use in the clinical laboratory. Arch. Pathol. Lab Med. 2015, 4:508-517.
25. Sims D., Sudbery I., Ilott N.E., Heger A., Ponting C.P. Sequencing depth and coverage: key considerations in genomic analyses. Nat. Rev. Genet. 2014, 15:121-132.
26. Singh R.R., Patel K.P., Routbort M.J., Reddy N.G., Barkoh B.A., Handal B., Kanagal-Shamanna R., Greaves W.O., Medeiros L.J., Aldape K.D., et al. Clinical validation of a next-generation sequencing screen for mutational hotspots in 46 cancer-related genes. J. Mol. Diagn.: JMD 2013, 15:607-622.
27. Tsimberidou A.M., Iskander N.G., Hong D.S., Wheler J.J., Falchook G.S., Fu S., Piha-Paul S., Naing A., Janku F., Luthra R., et al. Personalized medicine in a phase I clinical trials program: the MD Anderson Cancer Center initiative. Clin. Cancer Res.: Official J. Am. Assoc. Cancer Res. 2012, 18:6373-6383.
28. Yachida S., Jones S., Bozic I., Antal T., Leary R., Fu B., Kamiyama M., Hruban R.H., Eshleman J.R., Nowak M.A., et al. Distant metastasis occurs late during the genetic evolution of pancreatic cancer. Nature 2010, 467:1114-1117.
29. Yarmus L., Akulian J., Gilbert C., Feller-Kopman D., Lee H.J., Zarogoulidis P., Lechtzin N., Ali S.Z., Sathiyamoorthy V. Optimizing endobronchial ultrasound for molecular analysis. How many passes are needed?. Ann. Am. Thorac. Soc. 2013, 10:636-643.